Hiroyuki Nishiyama

ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

Thomas Powles, Zoe J. Assaf, Nicole N. Davarpanah et al. · Nature · 2021 · 604 citations

Medicine, Oncology, Urology +12

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

Arjun Vasant Balar, Ashish M. Kamat, Girish S. Kulkarni et al. · The Lancet Oncology · 2021 · 533 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

Joaquim Bellmunt, Maha Hussain, Jürgen E. Gschwend et al. · The Lancet Oncology · 2021 · 412 citations · Full text

Medicine, Oncology, Pharmacology +12

A Glycine-rich RNA-binding Protein Mediating Cold-inducible Suppression of Mammalian Cell Growth

Hiroyuki Nishiyama, Katsuhiko Itoh, Yoshiyuki Kaneko et al. · The Journal of Cell Biology · 1997 · 386 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +16

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

Thomas Powles, James W.F. Catto, Matthew D. Galsky et al. · New England Journal of Medicine · 2024 · 322 citations

Medicine, Surgery, Urology +14